2395 — Shin Nippon Biomedical Laboratories Income Statement
0.000.00%
Last trade - 00:00- ¥53bn
- ¥69bn
- ¥26bn
- 51
- 66
- 18
- 39
Annual income statement for Shin Nippon Biomedical Laboratories, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
| Standards: | JAS | JAS | JAS | JAS | JAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 14,561 | 15,111 | 17,748 | 25,091 | 26,450 |
| Cost of Revenue | |||||
| Gross Profit | 7,616 | 7,554 | 9,687 | 13,047 | 14,283 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 12,393 | 13,343 | 13,523 | 21,302 | 22,280 |
| Operating Profit | 2,169 | 1,767 | 4,226 | 3,789 | 4,171 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 3,063 | 4,176 | 8,183 | 7,760 | 6,974 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 2,648 | 3,678 | 7,167 | 6,051 | 5,518 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 2,550 | 3,662 | 7,128 | 6,060 | 5,531 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 2,550 | 3,662 | 7,128 | 6,060 | 5,531 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 62.5 | 77.8 | 148 | 174 | 136 |
| Dividends per Share | |||||
| Special Dividends per Share |